Floatz logo

Regn10597

Clear-Cell Renal-Cell Carcinoma (ccRCC)

Regeneron PharmaceuticalsPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Clear-Cell Renal-Cell Carcinoma (ccRCC) cohort.

Asset / SponsorPhaseRating
Everolimus
Peking University First Hospital
Phase 2BB
Axitinib
University of California, San Francisco
Phase 3B
Nivolumab
Exelixis
Phase 2B
gw786034
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2B
MODIFIED VACCINIA VIRUS ANKARA-5T4 ANTIGEN
Oxford BioMedica
Phase 3B

View all 39 →

Same molecule, other indications

Regn10597 is also rated in:

melanomaDormant
CC
Indicative ·
41 / 100
View asset →
cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →